RiskMetrics Supports Two From Icahn Slate For Biogen Idec (BIIB) Board
More News related to BIIB
- Trading Outlook for MannKind Corp. Issued by InvestorSoup.com
- Jefferies & Co Upgrades Biogen Idec (BIIB) to Buy
- Trading Outlook for Metabasis Therapeutics Issued by StockPreacher.com
- Trading Outlook for Incyte Corp. Issued by StockPreacher.com
- Subset Data from Two Randomized Phase 3 Trials Show TYSABRI Significantly Reduces Rates of Hospitalization in Patients with Moderate-to-Severe Crohn's Disease
RiskMetrics Group supports for two of Carl C. Icahn's nominees to Biogen Idec Inc.'s (Nasdaq: BIIB) board of directors. RiskMetrics recommended that stockholders of Biogen Idec vote for Dr. Alexander J. Denner and Dr. Richard C. Mulligan. In announcing its support, RiskMetrics stated: "...we conclude that the presence of dissident nominees Denner and Mulligan on the Biogen board would likely prove beneficial to long-term shareholder value."
Related Categories
Corporate NewsStocks Mentioned
+1.37Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
